AzTrials
AzTrials

Venous Leg UlcerPhase 4NAZARÉNCT06528873

COMS for Chronic Ulcers Treatment

A Phase 4 study testing Concurrent optical and magnetic stimulation (COMS) treatment in people with Venous Leg Ulcer and Wound Heal, run by Sebastian Probst at 10 sites in 4 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Concurrent optical and magnetic stimulation (COMS) treatment
Could I receive a placebo?
No, everyone receives an active treatment
How many people
122 participants
Where
10 sitesin 4 countries
Study dates
1 Oct 2025to 30 Sep 2026
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years Clinical diagnosis of venous leg ulcer (VLU) or VLU with peripheral arterial disease (PAD) Ankle-brachial index (ABI) 0.5-1.3 or ankle pressure > 60 mmHg Ulcer size 2-50 cm² after debridement at screening Ulcer duration > 30 days and < 2 years For patients with diabetes: HbA1c ≤ 12% at screening Able and willing to provide written informed consent prior to study procedures

Who cannot join

  • Pregnant or breastfeeding Malignancy in the ulcer area Use of photosensitizing medication within 30 days Severe immunosuppression (including chronic corticosteroid use > 10 mg/day prednisolone equivalent) NYHA class III or IV heart failure End-stage renal disease requiring dialysis Ulcer area reduction > 30% during run-in phase Active infection requiring systemic antibiotics at baseline Use of advanced wound therapies (e.g., negative pressure wound therapy, skin substitutes, hyperbaric oxygen) within 2 weeks prior to screening Participation in another interventional clinical trial within 30 days

Trial locations and contacts

10 sites in 4 countries. Contact the study team or a site near you to ask about taking part.

Sebastian Probst, Prof. Dr. contact

122-558-6563

sebastian.probst@hesge.ch

Camille Saini, Dr. contact

122-558-5274

camille.saini@hesge.ch

10 sites in 4 countries

Switzerland5 sites, 5 recruiting
  • Jura Hospital

    Delémont

    Claudio Ruzza, Dr., +41 32 421 27 93, Claudio.Ruzza@h-ju.ch

    Not yet recruiting
  • Venenklinik Bellevue

    Kreuzlingen

    Jürg Traber, Dr., +41 71 678 22 66, j.traber@venenklinik.ch

    Recruiting
  • Cité Générations

    Onex

    Dave Baer, Dr., +4122 709 00 00, dave.baer@cpo.ch

    Not yet recruiting
  • Spital Thun

    Thun

    Thomas Zehnder, Dr., +41 58 636 27 44, Thomas.Zehnder@spitalstsag.ch

    Not yet recruiting
  • University Hospital

    Zurich

    Jürg Hafner, Prof., +41 44 255 44 87, Juerg.hafner@usz.ch

    Not yet recruiting

Other trials in Switzerland

Austria2 sites, 2 recruiting
  • Medizinische Universität Graz

    Graz

    Lars-Peter Kamolz, Prof., +43 316 385-14685, lars.kamolz@medunigraz.at

    Not yet recruiting
  • Medizinische Universität Wien

    Vienna

    Benedikt Weber, Prof., +43 1 40400-77500, benedikt.weber@meduniwien.ac.at

    Not yet recruiting

Other trials in Austria

Germany2 sites, 2 recruiting
  • Universitätsklinikum Essen

    Essen

    Joachim Dissemond, Prof., +49 0201 723 36 41, Joachim.Dissemond@uk-essen.de

    Not yet recruiting
  • University Clinic Hamburg-Eppendorf

    Hamburg

    Ewa Stürmer, Prof., +49 0201 723 36 41, Joachim.Dissemond@uk-essen.de

    Not yet recruiting

Other trials in Germany

France1 site, 1 recruiting
  • Augustines's Clinic

    Malestroit

    Jean-Paul Lembelembe, Dr., +33 02 97 73 18 24, jplembelembe@ghsa.fr

    Not yet recruiting

Other trials in France

About this study

Official title: NAZARÉ: Concurrent Optical and Magnetic Stimulation (COMS) for Treatment of Patients With Chronic Ulcers of Vascular Origin in a Real-world Setting Including Care at Patient's Home, a Prospective Randomized, Controlled, Assessor Blinded, Phase IV, Clinical Trial

Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. These ulcers often result from macro- and microvascular disorders, the most common being chronic venous insufficiency (CVI), alone or with peripheral artery disease (PAD) or microangiopathy. Despite different causes, chronic vascular-origin wounds share similar biological traits and require the same physiological processes for healing.

Vascular issues hinder blood perfusion, reducing oxygen, nutrients, and growth factors, leading to decreased energy metabolism and impaired cell functions necessary for proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Reduced blood supply also limits leukocyte function, compromising the immune response and leading to persistent inflammation and infection. Consequently, these wounds cannot effectively heal, showing prolonged inflammation, persistent infections, and cellular senescence.

Read more

Best practice wound care includes compression therapy and physical activity for venous ulcers, and angioplasty, surgery, or bypass for arterial ulcers. These treatments aim to improve blood flow, reduce venous stasis, and enhance venous return. Compression therapy and physical activity lower hydrostatic pressure in the lower limb, while angioplasty and surgery remove arterial blockages or create new blood flow routes.

Recent studies highlight the role of mechano-sensitive (MS) ion channels in skin cell processes and their dysfunction in dermatological disorders. Magnetic stimulation can activate MS TRCP1 channels, enhancing mitochondrial respiration and mitochondriogenesis via the Ca2+/CalModulin(CaM)/NFAT/PGC-1α pathway. Ca2+-activated calmodulin also catalyzes nitric oxide (NO), promoting vasodilation and tissue perfusion.

Bimodal red and near-infrared photobiomodulation can further increase mitochondrial respiration and ATP production by activating Cytochrome C oxidase and mitigating NO-induced downregulation. This synergistic mechanism of concurrent optical and magnetic stimulation (COMS) may amplify Ca2+ and NO-mediated processes like cell proliferation, migration, vasodilation, and angiogenesis while resolving inflammation. Thus, COMS may offer a promising therapy for chronic, inflammation-prone wounds.

The effectiveness of COMS has yet to be validated in large-scale studies. This proposal aims to assess the impact of COMS therapy combined with standard care versus standard care alone on healing, wound closure, recurrence, pain, quality of life, economic outcomes, and device usability in patients with venous leg ulcers (VLU) and VLU associated with PAD in a large-scale multicentric randomized controlled trial.

Read the detailed description

Background: Chronic leg and foot ulcers are defined as wounds which fail to proceed through phases of wound healing in an orderly and timely manner to produce a durable structural functional and cosmetic closure. Depending on care setting / geographical region, wounds are considered chronic if they persist over more than 4 to 8 weeks with no substantial wound healing under standard of care (SOC) treatment regimen.

Among the most frequent causes for a delayed wound healing process are macro- and microvascular disorders. The most common is a chronic venous insufficiency (CVI), either as standalone or in combination with peripheral artery disease (PAD) or microangiopathy. Despite their differences in etiology, chronic wounds of vascular origin share similar biological features and require promotion of the same physiological processes for wound healing. The vascular constraints reduce blood perfusion and hinder appropriate cellular supply with oxygen, nutrients, and growth factors. This leads to decreased energy metabolism and therefore impaired cellular performance required for cell proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Additionally, reduced vascular supply decreases the number and ability of leukocytes to engage oxidative bursts, limiting the capacity for efficient pathogen destruction and leading to tissue devitalization. Consequently, the immune response becomes insufficient to deal with the local pathogen load, leading to ongoing inflammation in the wound area. In summary chronic wounds of vascular origins are unable to run through processes of wound healing, showing an inability to respond to local reparative stimuli of the wound environment, prolonged inflammation, persistent infections, and cellular senescence.

Best practice wound care emphasizes the utilization of compression therapy and physical activity for leg ulcers of venous etiology and angioplasty, surgery, or bypass operation for leg ulcers of arterial etiology, both axes of care being guided by the integration of healthcare professionals' clinical expertise with the best available clinical evidence. Compression therapy and physical activity facilitate wound healing by reducing hydrostatic pressure in the lower limb, mitigating venous stasis, and enhancing venous return. To improve the blood supply to the ulcer, angioplasty and surgery aims to clear out a blockage from a leg artery (endarterectomy), while bypass operation aims to put in a new route for blood flow in the leg.

Concurrent Optical and Magnetic Stimulation Recent publications have demonstrated the importance of mechano-sensitive (MS) ion channels in regulating processes such as skin cell proliferation, differentiation and barrier formation and linked their dysfunction to dermatological disorders. Magnetic stimulation has been shown to activate mechanosensitive TRCP1 channels, whereby the resulting ion channel-mediated calcium fluxes stimulate mitochondrial respiration and associated mitochondriogenesis through activation of the Ca2+/CalModulin(CaM) /NFAT/PGC-1α pathway. Ca2+-activated calmodulin has also been shown lead to the catalyzation of nitric oxide (NO), a potent mediator for vasodilation and tissue perfusion.

The concurrent bimodal red and near-infrared photo biomodulation, can further increase mitochondrial respiration and intracellular ATP production through activation of the Cytochrome C oxidase and mitigating its downregulation by increased levels of intracellular NO through its photo dissociation. Through this synergistic mechanism COMS may offer a therapeutic option for amplifying Ca2+ and NO mediated processes such as cell proliferation, migration, vasodilation, and angiogenesis while helping to shift the cytokine profile towards resolution of inflammation. Therefore, COMS may offer a promising therapeutic approach to enable the transition toward healing of therapy refractory wounds that tend to stay in inflammatory phase. The effectiveness of COMS has not yet been tested in a large-scale study. We propose here to assess the impact of COMS therapy+SOC versus SOC only, on healing, wound closure, wound recurrence, pain, quality of life, economic outcomes and device usability, in patients with venous leg ulcers (VLU) and VLU associated with PAD, in a large-scale multicentric randomized controlled trial.

Design: This study is a post market, phase IV clinical trial. A multicentric randomized controlled trial design will be used. 122 consecutive eligible patients with VLU or VLU associated with PAD, cared in outpatient or home settings in Switzerland (6 sites), France (1 site), Germany (2 sites) and Austria (2 sites), will be included and randomly allocated to one of the two study groups. Half of the participants will receive the standard of care (control group) and the other half will receive the standard of care, supplemented with COMS treatment during the 8 first week's post-inclusion (intervention group). Total study duration for each participant will be 24 weeks.

The intervention is single-blinded, i.e. it not blinded to participants and health care professionals but blinded to data assessors. Analysis:

The entire sample (intervention and control groups) will be described, according to the data level, in terms of their demographic and health data, using descriptive statistics. For the analysis of the different outcomes, the proportions or mean values will be compared between control and intervention groups by using classical tests of hypotheses. Additional analyses will be conducted to assess the change of the wound size over time and to compare groups. The statistical software for data science STATA 17.0 SAS version 9.4 or later (SAS Institute Inc., Cary, NC) will be used for data analysis.

Being tested
Concurrent optical and magnetic stimulation (COMS) treatment
Keywords
Venous leg ulcer, optical stimulation, magnetic stimulation
Medical subject headings
Varicose Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Concurrent optical and magnetic stimulation (COMS) treatmentCombination product

    COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:

    Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)

    If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device.

Study groups in NCT06528873
Study groupRoleWhat they receive
usual careNo interventionStandard of Care treatment will be performed according to a provided standard of care manual according to most recent guidelines followed at each corresponding site (EWMA , S3-Leitlinie,…) and will proceed as follows: * Removal of old dressing * Application of analgesic if necessary * Debridement if necessary * Wound cleansing * Application of new dressing (according to the wound healing phases, medical prescription) * Application of compression therapy according to study standardized procedure (details in section 6.1). In the case the participant is at home, this procedure will be performed by a caregiver.
COMS TherapyExperimentalCOMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps: Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1) If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device.
Receives: Combination Product: Concurrent optical and magnetic stimulation (COMS) treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent wound area reduction

    Percent wound area reduction (PWAR) at week 12 will be measured from pictures of the wound taken with ImitoWound research application. PWAR is computed as (Wound area at baseline - Wound area at 12 weeks) / Wound area at baseline.

    The picture of the wound will be taken after dressing removal, wound debridement (if applicable) and wound cleansing. ImitoWound research App will be used in an iPad as instructed in supplier's wound imaging and measurement guidelines. The camera of the iPad will be positioned 20 to 30 cm away from and parallel to the wound. A calibration marker (quick response [QR] code) will be positioned next to and in the same plane of the wound, and a photograph will be taken after recognition of the QR code by the Imito App, automatic wound measurement will take place. Study nurses will receive concise training and a working instruction with step-by-step procedure on how to use Imito App. (See Appendices) Each wound contour will then be checked and confirmed by an expe

    Measured: 24 weeks

Secondary outcomes (6)
  1. Complete wound closure

    1. Complete wound closure after 8, 12, 16, 20, 24 weeks. Complete wound closure is defined as complete skin re-epithelialization without drainage confirmed by 2 consecutive trial visits 2 weeks apart

    Measured: 24 weeks

  2. Percent Wound Area Reduction (PWAR

    Percent Wound Area Reduction (PWAR) at week 4, 8, 16, 20, 24 will be measured from pictures of the wound taken with ImitoWound

    Measured: 24 weeks

  3. Change in Pain assessment

    Change in Pain assessment at week 12 vs. week 0 (VAS Scale). Patient's perception in terms of pain will be assessed using Visual Analog Scale (VAS) from 0 (no pain) to 10 (very strong pain). It will be asked the participant to use this scale to give a measure of general pain perceived prior to any treatment. The use of VAS offers a widespread potential to document the characteristics of disease-related symptoms (Gethin et al. 2014). Such scales are successfully used in the assessment of wound-related symptoms, are inexpensive and easily understood.

    Measured: 24 weeks

  4. Change in Wound-QoL

    1. Change in Wound-QoL questionnaire at week 12 vs. week 0 (Wound-QoL). Wound-QoL is a short and easy-to-understand instrument to assess health related quality of life in patients with chronic wounds, especially leg ulcers. It consists of one page 17 Likert scaled items assessing impairments within the preceding seven days. Answers to each item are coded with numbers (0='not at all' to 4='very much'). A Wound-QoL-17 global score on overall disease-specific quality of life is computed by averaging all items. In addition, subscales of the Wound-QoL can be calculated representing different dimensions of disease-specific quality of life by averaging the respective items ("Body": items 1-5, "Psyche": items 6-10 and "Everyday life": items 11-16). Validated translations have been performed in French (France and Switzerland) and German (Germany, Austria and Switzerland).

    Measured: 24 weeks

  5. Median time-to-healing

    Median time-to-healing (50, 90, 100%) through up to week 24

    Measured: 24 weeks

  6. Ulcer re-occurrence rate

    Ulcer re-occurrence rate through up to week 24. Recurrence is when a VLU reopens in the same location after healing.

    Measured: 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jul 2024
  2. Study start1 Oct 2025
  3. Primary completion31 Aug 2026 (estimated)
  4. Study completion30 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Device feasibility
Allocation
Randomised
Intervention model
Single group
Model description
The COMS One therapy system is a CE-marked medical device for treating chronic leg and foot ulcers. It uses electromagnetic fields and photons non-invasively, non-ionizingly, non-thermally, and non-medicinally. The device transmits extremely low frequency (ELF) electromagnetic fields using a coil connected to a signal generator. It emits twenty trapezoid-shaped bursts per second, with the field's polarity switching every 2 minutes over a 16-minute session. The flux densities range from 0.4 mT to 1.6 mT in four-minute intervals. Photons are delivered via LEDs with peak wavelengths of 660 nm and 830 nm, targeting cytochrome C Oxidase. The light pulses at 1000 Hz, providing a radiant exposure of 2-5 J/cm² at a 1 cm distance from the skin. Technical details are in the IFU (100.0053\_C\_IfU).
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
122 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06528873
Sponsor's protocol ID
NAZARÉ
Other IDs
PIOMIC
Acronym
NAZARÉ
Status last verified
May 2026
First submitted
26 Jul 2024
Last updated
8 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Raw data will be shared using Yareta (https://yareta.unige.ch/home) a Swiss research platform using the FAIR priniples

Publications

  • Probst S, Saini C, Stefanelli A, Frei A, Stuermer EK, Dissemond J, Kamolz LP, Weber B, Lembelembe JP, Traber J, Mayer D, Zehnder T, Baer D, Ruzza C, Hafner J. Adjunctive optical and magnetic stimulation for venous and mixed etiology leg ulcers: protocol for the NAZARE multicenter randomized controlled trial. Trials. 2026 Jun 29. doi: 10.1186/s13063-026-09859-1. Online ahead of print.

    PubMed 42366370

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Concurrent optical and magnetic stimulation (COMS) treatment in people with Venous Leg Ulcer and Wound Heal, run by Sebastian Probst at 10 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in Switzerland, Austria, Germany, France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sebastian Probst, Prof. Dr. (122-558-6563, sebastian.probst@hesge.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent wound area reduction (time frame: 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06528873, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in